DNA variant affects diabetes risk and treatment response

A DNA variant near a digestive enzyme does not only affect risk of developing diabetes but also affects the response to treatment, an international consortium of researchers including the University of Dundee has found.

The study found that healthy volunteers with this DNA variant had an up to forty percent higher insulin response after stimulation with the hormone GLP-1, a likely explanation as to why they have a reduced chance of developing type 2 diabetes.

"It was already known that subjects carrying this variant have a reduced chance of developing type 2 diabetes," according to Dutch scientist Dr Leen 't Hart from Leiden University Medical Center, Leiden, The Netherlands, who is the lead author on the paper. "What we have been able to show is why they are less likely to develop type 2 diabetes

GLP-1 (-like peptide-1) is a hormone that is produced by the gut in response to a meal. One of its functions is to stimulate from the pancreas so that the elevated after a meal rapidly return to normal.

While the patients with the DNA variant were shown to be less likely to develop , it was also found that they actually respond worse to treatment with a novel class of drugs that improve GLP-1 function, called DPP4-inhibitors. These drugs, such as Sitagliptin and Vildagliptin, are being increasingly used to treat diabetes. It is not yet known how the DNA variant affects response to these drugs but researchers said it might be due to the observed increased activity of chymotrypsin in the intestines.

The research study was carried out by a consortium of researchers from the Netherlands, Germany, Denmark, Sweden and the United Kingdom and the results are published in the scientific journal Diabetes.

Professor Ewan Pearson, of the University of Dundee, said, "These novel findings provide new clues to better and treatment. This will be the subject of future experiments aiming to personalise treatment of diabetes, which is targeting specific treatments to an individual based upon his or her genetic features."

Related Stories

Importance of diabetes genetic variants unclear

Apr 04, 2012

(HealthDay) -- Genetic variants associated with type 2 diabetes that affect glucagon-like peptide 1 (GLP-1) are not associated with GLP-1 levels or GLP-1-induced insulin secretion in healthy individuals, according ...

Recommended for you

Blood glucose levels set for achieving HbA1c targets

Apr 11, 2014

(HealthDay)—The average self-monitored blood glucose (SMBG) concentrations needed at premeal, postmeal, and bedtime have been established to achieve a range of hemoglobin A1c (HbA1c) targets, according ...

Women with diabetes less likely to have a mammogram

Apr 11, 2014

Women with diabetes are 14 per cent less likely to be screened for breast cancer compared to women without diabetes, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's ...

Nonalcoholic fatty liver disease linked to CKD in T1DM

Apr 09, 2014

(HealthDay)—For patients with type 1 diabetes, nonalcoholic fatty liver disease (NAFLD) is independently associated with the risk of incident chronic kidney disease (CKD), according to a study published ...

User comments